Several other equities research analysts have also issued reports on OBSV. Zacks Investment Research upgraded shares of ObsEva SA from a sell rating to a hold rating in a research report on Friday. Leerink Swann reiterated an outperform rating and set a $18.00 target price on shares of ObsEva SA in a research report on Wednesday, August 16th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $23.25.
ObsEva SA (OBSV) opened at 6.995 on Friday. The firm’s market capitalization is $199.33 million. The company’s 50-day moving average is $7.51 and its 200-day moving average is $8.54. ObsEva SA has a 52-week low of $5.00 and a 52-week high of $14.70.
ObsEva SA (NASDAQ:OBSV) last announced its earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.13. During the same quarter last year, the company posted ($0.30) EPS. Analysts forecast that ObsEva SA will post ($2.32) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/12/obseva-sa-obsv-given-buy-rating-at-hc-wainwright.html.
A number of institutional investors have recently made changes to their positions in the business. NEA Management Company LLC bought a new stake in ObsEva SA during the first quarter valued at approximately $34,734,000. Sphera Funds Management LTD. lifted its holdings in shares of ObsEva SA by 9.7% in the 2nd quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock worth $1,979,000 after acquiring an additional 20,411 shares during the last quarter. Sectoral Asset Management Inc lifted its holdings in shares of ObsEva SA by 181.9% in the 2nd quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after acquiring an additional 137,331 shares during the last quarter. VHCP Management II LLC bought a new stake in shares of ObsEva SA in the 2nd quarter worth approximately $1,283,000. Finally, UBS Oconnor LLC bought a new stake in shares of ObsEva SA in the 1st quarter worth approximately $1,017,000. Institutional investors and hedge funds own 48.46% of the company’s stock.
ObsEva SA Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.